[tds_menu_login inline="yes" guest_tdicon="td-icon-profile" logout_tdicon="td-icon-log-out" tdc_css="eyJwaG9uZSI6eyJtYXJnaW4tcmlnaHQiOiIyMCIsIm1hcmdpbi1ib3R0b20iOiIwIiwibWFyZ2luLWxlZnQiOiI2IiwiZGlzcGxheSI6IiJ9LCJwaG9uZV9tYXhfd2lkdGgiOjc2N30=" toggle_hide="eyJwaG9uZSI6InllcyJ9" ia_space="eyJwaG9uZSI6IjAifQ==" icon_size="eyJhbGwiOjI0LCJwaG9uZSI6IjIwIn0=" avatar_size="eyJwaG9uZSI6IjIwIn0=" show_menu="yes" menu_offset_top="eyJwaG9uZSI6IjE4In0=" menu_offset_horiz="eyJhbGwiOjgsInBob25lIjoiLTMifQ==" menu_width="eyJwaG9uZSI6IjE4MCJ9" menu_horiz_align="eyJhbGwiOiJjb250ZW50LWhvcml6LWxlZnQiLCJwaG9uZSI6ImNvbnRlbnQtaG9yaXotcmlnaHQifQ==" menu_uh_padd="eyJwaG9uZSI6IjEwcHggMTVweCA4cHgifQ==" menu_gh_padd="eyJwaG9uZSI6IjEwcHggMTVweCA4cHgifQ==" menu_ul_padd="eyJwaG9uZSI6IjhweCAxNXB4In0=" menu_ul_space="eyJwaG9uZSI6IjYifQ==" menu_ulo_padd="eyJwaG9uZSI6IjhweCAxNXB4IDEwcHgifQ==" menu_gc_padd="eyJwaG9uZSI6IjhweCAxNXB4IDEwcHgifQ==" menu_bg="var(--news-hub-black)" menu_shadow_shadow_size="eyJwaG9uZSI6IjAifQ==" menu_arrow_color="rgba(0,0,0,0)" menu_uh_color="var(--news-hub-light-grey)" menu_uh_border_color="var(--news-hub-dark-grey)" menu_ul_link_color="var(--news-hub-white)" menu_ul_link_color_h="var(--news-hub-accent-hover)" menu_ul_sep_color="var(--news-hub-dark-grey)" menu_uf_txt_color="var(--news-hub-white)" menu_uf_txt_color_h="var(--news-hub-accent-hover)" menu_uf_border_color="var(--news-hub-dark-grey)" f_uh_font_size="eyJwaG9uZSI6IjEyIn0=" f_uh_font_line_height="eyJwaG9uZSI6IjEuMyJ9" f_uh_font_family="eyJwaG9uZSI6IjMyNSJ9" f_links_font_size="eyJwaG9uZSI6IjEyIn0=" f_links_font_line_height="eyJwaG9uZSI6IjEuMyJ9" f_links_font_family="eyJwaG9uZSI6IjMyNSJ9" f_uf_font_size="eyJwaG9uZSI6IjEyIn0=" f_uf_font_line_height="eyJwaG9uZSI6IjEuMyJ9" f_uf_font_family="eyJwaG9uZSI6IjMyNSJ9" f_gh_font_family="eyJwaG9uZSI6IjMyNSJ9" f_gh_font_size="eyJwaG9uZSI6IjEyIn0=" f_gh_font_line_height="eyJwaG9uZSI6IjEuMyJ9" f_btn1_font_family="eyJwaG9uZSI6IjMyNSJ9" f_btn1_font_weight="eyJwaG9uZSI6IjcwMCJ9" f_btn1_font_transform="eyJwaG9uZSI6InVwcGVyY2FzZSJ9" f_btn2_font_weight="eyJwaG9uZSI6IjcwMCJ9" f_btn2_font_transform="eyJwaG9uZSI6InVwcGVyY2FzZSJ9" f_btn2_font_family="eyJwaG9uZSI6IjMyNSJ9"]
3.8 C
New York
[tds_menu_login guest_tdicon="td-icon-profile" logout_tdicon="td-icon-log-out" tdc_css="eyJhbGwiOnsibWFyZ2luLWJvdHRvbSI6IjAiLCJkaXNwbGF5IjoiIn19" toggle_txt_color="var(--news-hub-white)" menu_offset_top="eyJhbGwiOiIxOSIsImxhbmRzY2FwZSI6IjE3IiwicG9ydHJhaXQiOiIxNSJ9" menu_offset_horiz="eyJhbGwiOi02LCJsYW5kc2NhcGUiOiItMyIsInBvcnRyYWl0IjoiLTIifQ==" menu_horiz_align="content-horiz-right" menu_bg="var(--news-hub-black)" menu_uh_color="var(--news-hub-light-grey)" menu_uh_border_color="var(--news-hub-dark-grey)" menu_ul_link_color="#ffffff" menu_ul_link_color_h="var(--news-hub-accent-hover)" menu_ul_sep_color="var(--news-hub-dark-grey)" menu_uf_txt_color="var(--news-hub-white)" menu_uf_txt_color_h="var(--news-hub-accent-hover)" menu_uf_border_color="var(--news-hub-dark-grey)" f_uh_font_family="325" f_uh_font_line_height="1.3" f_links_font_family="325" f_links_font_line_height="1.3" f_uf_font_line_height="1.3" f_uf_font_family="325" menu_uh_padd="eyJhbGwiOiIyMHB4IDI1cHggMThweCIsImxhbmRzY2FwZSI6IjE1cHggMjBweCAxM3B4IiwicG9ydHJhaXQiOiIxMHB4IDE1cHggOHB4In0=" menu_ul_padd="eyJhbGwiOiIxOHB4IDI1cHgiLCJsYW5kc2NhcGUiOiIxNnB4IDIwcHgiLCJwb3J0cmFpdCI6IjhweCAxNXB4In0=" menu_ul_space="eyJhbGwiOiIxMCIsImxhbmRzY2FwZSI6IjgiLCJwb3J0cmFpdCI6IjYifQ==" menu_ulo_padd="eyJhbGwiOiIxOHB4IDI1cHggMjBweCIsImxhbmRzY2FwZSI6IjEzcHggMjBweCAxNXB4IiwicG9ydHJhaXQiOiI4cHggMTVweCAxMHB4In0=" menu_shadow_shadow_size="0" menu_arrow_color="rgba(255,255,255,0)" menu_width="eyJhbGwiOiIyMjAiLCJwb3J0cmFpdCI6IjE4MCJ9" show_version="" menu_gh_padd="eyJhbGwiOiIyMHB4IDI1cHggMThweCIsImxhbmRzY2FwZSI6IjE1cHggMjBweCAxM3B4IiwicG9ydHJhaXQiOiIxMHB4IDE1cHggOHB4In0=" menu_gc_padd="eyJhbGwiOiIxOHB4IDI1cHggMjBweCIsImxhbmRzY2FwZSI6IjEzcHggMjBweCAxNXB4IiwicG9ydHJhaXQiOiI4cHggMTVweCAxMHB4In0=" menu_gh_color="var(--news-hub-light-grey)" menu_gh_border_color="var(--news-hub-dark-grey)" f_gh_font_family="325" menu_gc_btn1_bg_color="var(--news-hub-accent)" menu_gc_btn1_bg_color_h="var(--news-hub-accent-hover)" menu_gc_btn2_color="var(--news-hub-accent)" menu_gc_btn2_color_h="var(--news-hub-accent-hover)" f_btn1_font_family="325" f_btn1_font_transform="uppercase" f_btn2_font_family="325" f_btn2_font_transform="uppercase" f_btn1_font_weight="700" f_btn2_font_weight="700" show_menu="yes" f_uf_font_size="eyJsYW5kc2NhcGUiOiIxMiIsInBvcnRyYWl0IjoiMTIifQ==" icon_color="var(--news-hub-white)" icon_size="eyJhbGwiOjIyLCJsYW5kc2NhcGUiOiIyMCIsInBvcnRyYWl0IjoiMTgifQ==" avatar_size="eyJhbGwiOiIyMiIsImxhbmRzY2FwZSI6IjIwIiwicG9ydHJhaXQiOiIxOCJ9" ia_space="eyJhbGwiOiIxMCIsImxhbmRzY2FwZSI6IjgiLCJwb3J0cmFpdCI6IjYifQ==" f_toggle_font_family="325" f_toggle_font_size="eyJhbGwiOiIxNCIsImxhbmRzY2FwZSI6IjEzIiwicG9ydHJhaXQiOiIxMiJ9" logout_size="eyJhbGwiOjE0LCJsYW5kc2NhcGUiOiIxMyJ9" f_uh_font_size="eyJsYW5kc2NhcGUiOiIxMyIsInBvcnRyYWl0IjoiMTIifQ==" f_links_font_size="eyJsYW5kc2NhcGUiOiIxMyIsInBvcnRyYWl0IjoiMTIifQ==" f_gh_font_size="eyJsYW5kc2NhcGUiOiIxMyIsInBvcnRyYWl0IjoiMTIifQ=="]
News

Apple Might Launch Its Own Smart Home Camera As It Focuses On Providing A More Integrated Product Experience For Its Users

Wccftech.com - 0
Apple is increasingly focusing on building its own devices and expanding its ecosystem by taking steps towards a more native experience for users and relying less on third-party accessories. While the Cupertino-based tech giant's HomePod and AppleTV have left quite the mark in the smart home category, it generally relies more on outsourcing cameras and other hardware for smart homes. Now, a new report suggests that the company intends to create a fully integrated experience by developing its own smart home accessories. Gurman hints about Apple working on making smart home products like security cameras for a more integrated experience […]
Deals

Best of Black Friday 2024 – power stations and bundles: Anker SOLIX, Bluetti, EcoFlow, Jackery

9to5Toys.com - 0
We’re continuing our Best of Black Friday posts today with a look at the best current deals on power stations and their respective bundle options. Folks across the country and beyond have been steadily investing more and more in the industry for a vari...
gaming

World Of Warcraft Is Finally Getting Player Homes After 20 Years

Kotaku.com - 0
Blizzard has announced that two decades after its release, World of Warcraft is finally going to let players build a home and live in it. The feature has long been requested by WoW players and now it’s finally coming in the game’s next expansion.Read m...
News

ArenaNet To Release ‘Godspawn’ Update for Guild Wars 2: Janthir Wilds on November 19, Featuring New 50-Player Titan Battle and More

Wccftech.com - 0
Guild Wars 2: Janthir Wilds will receive the Godspawn update, adding a new 50-player boss battle, a new 10-player raid, and a legendary spear. Guild Wars 2: Janthir Wilds is getting the first major update "Godspawn" on November 19th, expanding the story with new story chapters The MMORPG Guild Wars 2 by ArenaNet is receiving its first major update for the Janthir Wilds expansion soon. It's the first of three major updates, and it'll land on November 19. The update will add new content to the game for the players. The Janthir Wilds expansion DLC was released in August this year, […]

Score a 2TB 7,400MB/s Nextorage heatsink SSD compatible with PS5 at $110 low

Classic RTS Games Warcraft and Warcraft 2 Fully Remastered And Out Now

Native Union Classic Apple Watch Strap with soft nubuck leather lining now $20 (Reg. up to $60)

Amazon has ENGWE’s E26 dual suspension all-terrain e-bike hitting a new $849 low (Reg. $1,399)

Hello! Score 50% off Sam’s Club memberships just in time for the holidays at $25 (Reg. $50)

Dragon Age: The Veilguard’s Hardest Choice Has Fans Scouring For A Way Out

Spigen’s Titanium Keychain Multi-tool with knife, bottle opener, and carabiner now $34 (50% off)

NVIDIA’s DLSS 3.8.10 Package Reduces Preset Modes To Just Two Profiles, Drastically Reducing DLL File Size

Xbox Boss Says No ‘Red Line’ With Exclusives, Including Even Halo

PlayStation Store and Xbox gift cards now on sale from $9 ahead of upcoming Black Friday sales

Apple Will Launch A New ‘Command Center’ Home Device In March With Apple Intelligence Integration, As It Steps Into The Home Industry

Heybike’s Cityrun commuter e-bike carries you up to 55 miles of travel on a four-hour charge at $999 low (Save $600), more

Get two fully adjustable foldable smartphone holders on rotating metal bases at just $8 Prime shipped ($4 ea.)

What did the snowball Earth look like?

PlayStation Plus Brings Back Grand Theft Auto V And A Bunch Of Other Big Games

How Valve made Half-Life 2 and set a new standard for future games

Apple’s MetalFX Upscaling Comparison At 1080p Running Resident Evil 4 Remake Shows Reduced Image Quality, But Framerate Gets Up To 44 Percent Performance Bump

Here’s Our Favorite Cosplay From Dragon Con 2024

Nordstrom’s Early Black Friday Sale is live! Save up to 60% off Nike, Cole Haan, On Cloud, more

Latest Bose Ultra Open earbuds with spatialized audio return to $249 Amazon low

News

Some Analysts Do Not Want You To Write Off Madrigal In Favor Of Eli Lilly And Company’s GLP-1 Agonist For The Treatment Of Fatty...

Wccftech.com - 0
Eli Lilly and Company (NYSE: LLY) is currently one of the two primary darlings of Wall Street when it comes to thematic investing around anti-obesity GLP-1 drugs, with Novo Nordisk constituting the other end of this emerging duopoly. Yet, it is the precise heft of these two pharma giants that continues to present emergent opportunities to their smaller counterparts, especially in obesity-related diseases such as the Metabolic dysfunction-Associated Steatohepatitis (MASH, previously known as Nonalcoholic Ateatohepatitis or NASH). For the benefit of those who might not be aware, MASH is a fatty liver disease that develops primarily due to metabolic disorders, including […]
Read more
News

Eli Lilly and Company’s Tirzepatide GLP-1 Weight Loss Drug Is Now Poised To Shrink the Market for Breathing Machines

Wccftech.com - 0
What if a single pharmaceutical intervention regime could not only sustainably shrink your waistline but also cure your Obstructive Sleep Apnea (OSA)? This seems too good to be true. Yet, Eli Lilly and Company's (NYSE: LLY) Tirzepatide GLP-1 drug seems to have achieved just that. Eli Lilly and Company’s "Tirzepatide Led to a Mean AHI Reduction From Baseline of 62.8% Compared to 6.4% From Baseline for Placebo," as per the Results of the SURMOUNT-OSA Study 2. To wit, Eli Lilly and Company has now announced the results of two studies that investigated the impact of its Tirzepatide GLP-1 offering on […]
Read more
News

Eli Lilly and Company (LLY) Hits a New All-Time High as the Craze for GLP-1 Weight Loss Drugs Goes Global

Wccftech.com - 0
The soaring demand for GLP-1 weight loss drugs is no longer just an American or European phenomenon. As these drugs proliferate through an ever-increasing segment of the globe's obese population, the GLP-1 heavyweights such as Eli Lilly and Company and Novo Nordisk continue to reap outsized rewards. The Ozempic effect: According to Goldman Sachs, the reduction in obesity-related health concerns could boost U.S. GDP by 0.4% to 1% with widespread uptake of weight-loss medications — Julian Klymochko (@JulianKlymochko) March 3, 2024 GLP-1 drugs can induce significant weight loss by suppressing hunger and regulating the production of insulin and glucose. Eli […]
Read more
News

Cutting-Edge Biotech: A Novel Gene Therapy That Reverses Aging and a New Oral GLP-1 Drug From Viking Therapeutics

Wccftech.com - 0
There is a reason why biotech is considered a very volatile sector. After all, fortunes are made and destroyed within a few seconds in this sphere, dictated by the outcome of clinical trials for experimental therapies. Fortunately, over the past few days, we've received some very encouraging news on two unrelated but equally important vectors for improving the overall quality of human life: a new gene therapy that has the potential to significantly extend the human lifespan and a new oral GLP-1 weight loss drug candidate from Viking Therapeutics (NASDAQ: VKTX). Viking Therapeutics’ Oral GLP-1 Weight Loss Drug Is Out […]
Read more
News

Morgan Stanley: Oral GLP-1 Weight Loss Drug Can Propel Eli Lilly and Company to a $1 Trillion Valuation

Wccftech.com - 0
Eli Lilly and Company (NYSE: LLY) can become the first biopharma company to reach the $1 trillion valuation threshold, courtesy of an under-trial orally administered GLP-1 drug, Orforglipron, as per the latest investment note from Morgan Stanley. $LLY Eli Lilly Has Upside, May Reach $1 Trillion, Says Morgan Stanley (Bloomberg) - PT raised to a Street-high $950 from $805; shares closed at $757.78 on Thursday pic.twitter.com/0LgV0KfrLv — Christian Fromhertz 🇺🇸 (@cfromhertz) February 16, 2024 To wit, Morgan Stanley's Terence Flynn sees Orforglipron's phase three trial results, due in 2025, as a key catalyst for Eli Lilly and Company, paving the […]
Read more
News

Eli Lilly and Company’s Tirzepatide GLP-1 Agonist For Weight Loss Reverses Fatty Liver Disease in a “Clinically Meaningful” Way

Wccftech.com - 0
Hardly a week seems to go by without something positive emerging from either Eli Lilly and Company (LLY) or its other major competitor, Novo Nordisk (NVO), on the prospects of the GLP-1 weight loss drugs. The ongoing week has again held true to this emerging bullish regimen, with Eli Lilly garnering significant positive developments in the battle to counter Metabolic dysfunction-Associated Steatohepatitis (MASH, previously known as Nonalcoholic Ateatohepatitis or NASH). For the benefit of those who might not be aware, MASH is a fatty liver disease that develops most often due to metabolic disorders, including obesity and diabetes. This accumulation […]
Read more
News

The Penetration of GLP-1 Weight Loss Drugs Declines for the Second Consecutive Month but Analysts Say This Is a Blip

Wccftech.com - 0
If you weren't already aware, GLP-1 weight loss drugs from the likes of Novo Nordisk and Eli Lilly and Company are the biotech sphere's new craze, managing to rope in seasoned analysts who appear to be salivating at the prospect of billions of dollars in additional revenue streams. Yet, the hype seems to have lost some of its patina recently. TD COWEN: “.. surprised to see two months in a row of declines in the number of people who describe themselves as current users of GLP-1s. .. We believe this is a function of capacity constraints .. Penetration rates may […]
Read more
News

Zealand’s Amylin Is the Underdog That Has Dared To Challenge the Might of GLP-1 Weight Loss Drug Heavyweights

Wccftech.com - 0
The market for weight loss drugs is big enough to allow a plethora of competitors to thrive, as per the prevailing thesis. And we are not just talking about GLP-1 agonists from heavyweights such as Novo Nordisk and Eli Lilly and Company but also newer concoctions, including Amylin-based treatment that is being championed by Zealand. However, it is the unusual agility that is being demonstrated by the reigning Goliaths in this sphere that continues to limit the ascendancy of upstarts. As our regular readers would know, we maintain a generally positive view of weight loss treatments that leverage GLP-1 agonists. […]
Read more
News

Want To Find Out the Level of Hype Surrounding the GLP-1 Weight Loss Drugs? Just Look at This Comparison Between Eli Lilly and Company...

Wccftech.com - 0
The burgeoning hype around GLP-1 weight loss drugs as a panacea for the obesity pandemic has propelled Eli Lilly and Company (LLY) shares to previously unimaginable zeniths while leaving Pfizer (PFE), a former darling of the pharma world, in the proverbial dust bowl. One of the most eye-opening charts you'll see right now, this shows Eli Lilly's $LLY price to sales ratio vs Pfizer's $PFE price to sales ratio over time. Lilly is up to 18x versus Pfizer's 2x. The two were roughly the same in early 2021. pic.twitter.com/g9ycAWBEiM — Bespoke (@bespokeinvest) January 19, 2024 As is shown in the […]
Read more
News

Eli Lilly and Company (LLY) Comes Out Against the Use of GLP-1 Drugs for “Cosmetic Weight Loss” as Obesity in the US Remains Near...

Wccftech.com - 0
Eli Lilly and Company (LLY) is out today with a much-needed qualifier regarding the emergent probability of its breakthrough GLP-1 weight loss treatments ending up as "lifestyle drugs of choice." To wit, Eli Lilly and Company has now published an open letter, noting among other things: "Mounjaro and Zepbound are indicated for the treatment of serious diseases; they are not approved for – and should not be used for – cosmetic weight loss." While addressing the emerging issues with off-label Tirzepatide-based cocktails, Eli Lilly and Company writes: "Lilly is extremely concerned that some of the compounded Tirzepatide that Lilly has […]
Read more
News

Life-Long Commitment: A New Study Says That Over Half of the Weight Lost Through GLP-1 Drugs Such as Zepbound Comes Back After Quitting

Wccftech.com - 0
GLP-1 drugs have been billed as the long-awaited panacea for the obesity pandemic that continues to ravage an ever-increasing segment of the global population. However, a new study published today has shed fresh limelight on the limitations associated with relying solely on pharmaceutical interventions to achieve an ideal BMI. Glucagon-Like Peptide-1 (GLP-1) hormone plays an important role in regulating hunger. Novo Nordisk sells its Semaglutide GLP-1 drugs under the Ozempic and Wegovy labels. Eli Lilly and Company, on the other hand, sells its Tirzepatide GLP-1 cocktail under the Mounjaro and Zepbound labels. These drugs stimulate the release of insulin in […]
Read more
News

Eli Lilly and Company’s GLP-1 Weight Loss Drug Is Now Available in the US for as Low as $25

Wccftech.com - 0
One of the biggest hurdles to the mass appeal of a new class of GLP-1 weight loss drugs remains their sky-high prices. Insurance coverage, however, is playing a fundamental role in addressing these affordability concerns, with Eli Lilly and Company coming out today with important price updates for those with insurance coverage in the US. Glucagon-Like Peptide-1, or GLP-1 for short, plays an important role in regulating hunger. These drugs stimulate the release of insulin in the pancreas, block the unhelpful release of glucagon after meals to prevent excess glucose from entering the bloodstream, and slow gastric emptying to reduce […]
Read more

Tag: Eli Lilly and Company

How To Unlock Every Hero And Weapon Evolution In Vampire Survivors Ode To Castlevania DLC

gaming
Vampire Survivors draws tons of inspiration from Castlevania, so it is no surprise that the new Ode To Castlevania DLC is fantastic. I’m here to guide you through unlocking each Hero and evolving each weapon, because that’s how you’ll end up accessing ...

Overwatch Players, Y’all Lived Like This In 2016?

gaming
I started playing Overwatch in 2019. By the time I was pushing payloads and getting Play of the Game with a well-placed Tactical Visor, a lot of the old hero kits and team compositions that were infamous when the hero shooter launched in 2016 were more...

Some Analysts Do Not Want You To Write Off Madrigal In Favor Of Eli Lilly And Company’s GLP-1 Agonist For The Treatment Of Fatty...

News
Eli Lilly and Company (NYSE: LLY) is currently one of the two primary darlings of Wall Street when it comes to thematic investing around anti-obesity GLP-1 drugs, with Novo Nordisk constituting the other end of this emerging duopoly. Yet, it is the precise heft of these two pharma giants that continues to present emergent opportunities to their smaller counterparts, especially in obesity-related diseases such as the Metabolic dysfunction-Associated Steatohepatitis (MASH, previously known as Nonalcoholic Ateatohepatitis or NASH). For the benefit of those who might not be aware, MASH is a fatty liver disease that develops primarily due to metabolic disorders, including […]

Eli Lilly and Company’s Tirzepatide GLP-1 Weight Loss Drug Is Now Poised To Shrink the Market for Breathing Machines

News
What if a single pharmaceutical intervention regime could not only sustainably shrink your waistline but also cure your Obstructive Sleep Apnea (OSA)? This seems too good to be true. Yet, Eli Lilly and Company's (NYSE: LLY) Tirzepatide GLP-1 drug seems to have achieved just that. Eli Lilly and Company’s "Tirzepatide Led to a Mean AHI Reduction From Baseline of 62.8% Compared to 6.4% From Baseline for Placebo," as per the Results of the SURMOUNT-OSA Study 2. To wit, Eli Lilly and Company has now announced the results of two studies that investigated the impact of its Tirzepatide GLP-1 offering on […]

Eli Lilly and Company (LLY) Hits a New All-Time High as the Craze for GLP-1 Weight Loss Drugs Goes Global

News
The soaring demand for GLP-1 weight loss drugs is no longer just an American or European phenomenon. As these drugs proliferate through an ever-increasing segment of the globe's obese population, the GLP-1 heavyweights such as Eli Lilly and Company and Novo Nordisk continue to reap outsized rewards. The Ozempic effect: According to Goldman Sachs, the reduction in obesity-related health concerns could boost U.S. GDP by 0.4% to 1% with widespread uptake of weight-loss medications — Julian Klymochko (@JulianKlymochko) March 3, 2024 GLP-1 drugs can induce significant weight loss by suppressing hunger and regulating the production of insulin and glucose. Eli […]

Cutting-Edge Biotech: A Novel Gene Therapy That Reverses Aging and a New Oral GLP-1 Drug From Viking Therapeutics

News
There is a reason why biotech is considered a very volatile sector. After all, fortunes are made and destroyed within a few seconds in this sphere, dictated by the outcome of clinical trials for experimental therapies. Fortunately, over the past few days, we've received some very encouraging news on two unrelated but equally important vectors for improving the overall quality of human life: a new gene therapy that has the potential to significantly extend the human lifespan and a new oral GLP-1 weight loss drug candidate from Viking Therapeutics (NASDAQ: VKTX). Viking Therapeutics’ Oral GLP-1 Weight Loss Drug Is Out […]

Morgan Stanley: Oral GLP-1 Weight Loss Drug Can Propel Eli Lilly and Company to a $1 Trillion Valuation

News
Eli Lilly and Company (NYSE: LLY) can become the first biopharma company to reach the $1 trillion valuation threshold, courtesy of an under-trial orally administered GLP-1 drug, Orforglipron, as per the latest investment note from Morgan Stanley. $LLY Eli Lilly Has Upside, May Reach $1 Trillion, Says Morgan Stanley (Bloomberg) - PT raised to a Street-high $950 from $805; shares closed at $757.78 on Thursday pic.twitter.com/0LgV0KfrLv — Christian Fromhertz 🇺🇸 (@cfromhertz) February 16, 2024 To wit, Morgan Stanley's Terence Flynn sees Orforglipron's phase three trial results, due in 2025, as a key catalyst for Eli Lilly and Company, paving the […]

Eli Lilly and Company’s Tirzepatide GLP-1 Agonist For Weight Loss Reverses Fatty Liver Disease in a “Clinically Meaningful” Way

News
Hardly a week seems to go by without something positive emerging from either Eli Lilly and Company (LLY) or its other major competitor, Novo Nordisk (NVO), on the prospects of the GLP-1 weight loss drugs. The ongoing week has again held true to this emerging bullish regimen, with Eli Lilly garnering significant positive developments in the battle to counter Metabolic dysfunction-Associated Steatohepatitis (MASH, previously known as Nonalcoholic Ateatohepatitis or NASH). For the benefit of those who might not be aware, MASH is a fatty liver disease that develops most often due to metabolic disorders, including obesity and diabetes. This accumulation […]

The Penetration of GLP-1 Weight Loss Drugs Declines for the Second Consecutive Month but Analysts Say This Is a Blip

News
If you weren't already aware, GLP-1 weight loss drugs from the likes of Novo Nordisk and Eli Lilly and Company are the biotech sphere's new craze, managing to rope in seasoned analysts who appear to be salivating at the prospect of billions of dollars in additional revenue streams. Yet, the hype seems to have lost some of its patina recently. TD COWEN: “.. surprised to see two months in a row of declines in the number of people who describe themselves as current users of GLP-1s. .. We believe this is a function of capacity constraints .. Penetration rates may […]

Zealand’s Amylin Is the Underdog That Has Dared To Challenge the Might of GLP-1 Weight Loss Drug Heavyweights

News
The market for weight loss drugs is big enough to allow a plethora of competitors to thrive, as per the prevailing thesis. And we are not just talking about GLP-1 agonists from heavyweights such as Novo Nordisk and Eli Lilly and Company but also newer concoctions, including Amylin-based treatment that is being championed by Zealand. However, it is the unusual agility that is being demonstrated by the reigning Goliaths in this sphere that continues to limit the ascendancy of upstarts. As our regular readers would know, we maintain a generally positive view of weight loss treatments that leverage GLP-1 agonists. […]

Want To Find Out the Level of Hype Surrounding the GLP-1 Weight Loss Drugs? Just Look at This Comparison Between Eli Lilly and Company...

News
The burgeoning hype around GLP-1 weight loss drugs as a panacea for the obesity pandemic has propelled Eli Lilly and Company (LLY) shares to previously unimaginable zeniths while leaving Pfizer (PFE), a former darling of the pharma world, in the proverbial dust bowl. One of the most eye-opening charts you'll see right now, this shows Eli Lilly's $LLY price to sales ratio vs Pfizer's $PFE price to sales ratio over time. Lilly is up to 18x versus Pfizer's 2x. The two were roughly the same in early 2021. pic.twitter.com/g9ycAWBEiM — Bespoke (@bespokeinvest) January 19, 2024 As is shown in the […]

Eli Lilly and Company (LLY) Comes Out Against the Use of GLP-1 Drugs for “Cosmetic Weight Loss” as Obesity in the US Remains Near...

News
Eli Lilly and Company (LLY) is out today with a much-needed qualifier regarding the emergent probability of its breakthrough GLP-1 weight loss treatments ending up as "lifestyle drugs of choice." To wit, Eli Lilly and Company has now published an open letter, noting among other things: "Mounjaro and Zepbound are indicated for the treatment of serious diseases; they are not approved for – and should not be used for – cosmetic weight loss." While addressing the emerging issues with off-label Tirzepatide-based cocktails, Eli Lilly and Company writes: "Lilly is extremely concerned that some of the compounded Tirzepatide that Lilly has […]

Life-Long Commitment: A New Study Says That Over Half of the Weight Lost Through GLP-1 Drugs Such as Zepbound Comes Back After Quitting

News
GLP-1 drugs have been billed as the long-awaited panacea for the obesity pandemic that continues to ravage an ever-increasing segment of the global population. However, a new study published today has shed fresh limelight on the limitations associated with relying solely on pharmaceutical interventions to achieve an ideal BMI. Glucagon-Like Peptide-1 (GLP-1) hormone plays an important role in regulating hunger. Novo Nordisk sells its Semaglutide GLP-1 drugs under the Ozempic and Wegovy labels. Eli Lilly and Company, on the other hand, sells its Tirzepatide GLP-1 cocktail under the Mounjaro and Zepbound labels. These drugs stimulate the release of insulin in […]

Eli Lilly and Company’s GLP-1 Weight Loss Drug Is Now Available in the US for as Low as $25

News
One of the biggest hurdles to the mass appeal of a new class of GLP-1 weight loss drugs remains their sky-high prices. Insurance coverage, however, is playing a fundamental role in addressing these affordability concerns, with Eli Lilly and Company coming out today with important price updates for those with insurance coverage in the US. Glucagon-Like Peptide-1, or GLP-1 for short, plays an important role in regulating hunger. These drugs stimulate the release of insulin in the pancreas, block the unhelpful release of glucagon after meals to prevent excess glucose from entering the bloodstream, and slow gastric emptying to reduce […]
12Page 1 of 2

Recent articles

spot_img

©Patti.tech 2022